INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2 H Einsele; S Parekh; D Madduri; B Santomasso; JG Pérez-Larraya; NWV Donk; B Arnulf; M Mateos; KC Braganca; H Varsos; MJ Carrasco-Alfonso; M Akram; N Lendvai; CC Jackson; Y Olyslager; E Zudaire; C Li; D Geng; A Jakubowiak; A Cohen;

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1¿3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY ME Agha; AD Cohen; D Madduri; YC Cohen; M Delforge; J Hillengass; H Goldschmidt; K Weisel; M Raab; C Scheid; JM Schecter; KC Braganca; H Varsos; L Wang; M Vogel; MJ Carrasco-Alfonso; M Akram; X Wu; T Nesheiwat; H Einsele;

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY E Crusoe; T Facon; P Moreau; I Spicka; K Suzuki; K Yong; J Mikhael; T Fukao; N Armstrong; T Martin;